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Summary 
 
The liver flukes, Fasciola hepatica and gigantica are the causative agents of fascioliasis 
(fasciolosis). This parasitic disease is distributed throughout the world and exhibits a 
broad zoonotic reservoir, with farm animals such as sheep and cattle being the most 
important natural end hosts from an economic point of view. Since the 1990s fascioliasis 
is recognized as an increasing global public health problem with an estimated number of 
2.4 to 17 million individuals infected worldwide. Novel treatment options are needed, 
since triclabendazole is the sole drug recommended for human use and chemotherapy 
failure due to drug resistance is observed in livestock.  
 
Peroxidic compounds including the semisynthetic artemisinins, artesunate and 
artemether, as well as the artemisinin-like synthetic 1,2,4-trioxolane OZ78 exhibit 
promising in vitro and in vivo fasciocidal activity against juvenile and adult flukes. 
Moreover, it has been shown that these peroxides were active against a triclabendazole 
resistant F. hepatica strain.  
 
In the framework of this PhD thesis preclinical investigations were carried out to further 
strengthen our knowledge on the potential of the semisynthetic artemisinins, artesunate 
and artemether, for the treatment of F. hepatica infections. Moreover, the FLOTAC 
technique, a novel copromicroscopic technique, was evaluated for the detection and 
quantification of F. hepatica eggs in faecal samples.  
 
A sensitive copromicroscopic technique was required to examine F. hepatica infections 
intensities in experimentally infected rats or naturally infected sheep and to estimate 
the egg burden reduction after treatment in chemotherapy studies. Therefore, we 
compared the sedimentation technique, which is the reference copromicroscopic 
method, with the FLOTAC techniques for the detection and quantification of F. hepatica 
eggs in faecal samples obtained from experimentally infected rats. In low infection 
intensities, the sedimentation technique needed a rigorous reading effort with 8 slides 
examined to achieve a comparable sensitivity as a single FLOTAC (85.2% vs. 92.6%). 
Sensitivity was not an issue for both techniques analysing high infection intensities. 
Overall, the sedimentation technique is more uniform and easier to handle than FLOTAC, 
but the high reading effort needed to obtain a good sensitivity made it less time efficient. 
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For this reason FLOTAC and not the sedimentation technique was chosen for future 
copromicroscopic measurements carried out in our laboratories.  
 
The FLOTAC technique was successfully applied to identify sheep naturally infected with 
F. hepatica, to quantify their egg loads for allocating the animals in balanced treatment 
groups, and for evaluating treatment outcome on egg excretion. Sheep naturally infected 
with F. hepatica were treated with single doses of either artesunate or artemether using 
different routes of applications. Both drugs showed good activities against F. hepatica 
following intramuscular treatments, whereas artesunate required approximately a 
fourth of the artemether dose to obtain similar good activity. Oral treatments lacked 
activity in sheep. To strengthen the efficacy data, pharmacokinetic analyses of 
artemether and artesunate following different routes of application and doses were 
performed. 
 
A liquid chromatography tandem mass spectrometry (LC-MS/MS) method was 
developed and validated in terms of accuracy, precision and selectivity for the 
simultaneous quantification of artesunate, artemether and their metabolites 
dihydroartemisinin (DHA) and dihydroartemisinin-glucuronide (DHA-glucuronide) in 
sheep plasma for the later application to pharmacokinetic studies. The latter metabolite 
was identified in a preliminary analysis and was included in the pharmacokinetic study, 
since major plasma levels were observed. Plasma sample workup was performed using a 
simple protein precipitation method resulting in relative recoveries of 60-80%. All 
analytes were detected in the positive mode using selected reaction monitoring with a 
transition of m/z 267.4→163.0. The developed method demonstrated to be accurate, 
precise, and selective and achieved a lower limit of quantification of approximately 10 
ng/ml for artesunate, DHA, and DHA-glucuronide and of 90 ng/ml for artemether.  
 
The pharmacokinetic profiles of artesunate following intramuscular treatments were 
characterised by rapid drug invasion with Tmax of 15 min observed for artesunate and 
high Cmax and AUCs observed for all analytes. Moreover, drug elimination occurred fast 
with estimated t1/2 of 58-63 min, 94-113 min, and 89-98 min for artesunate, DHA and 
DHA-glucuronide. On the other hand, a slow liberation of artemether from the oil-based 
drug formulation with more or less constant levels of artemether and its metabolites 
during the entire sampling period of 24 h was observed following intramuscular 
application. In consequence, low Cmax of all analytes were detected following artemether 
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im treatments compared to artesunate. However, the calculated AUCs of effective 
artemether treatments (160 mg/kg) were comparable with those of the effective 
artesunate applications (40 and 60 mg/kg). Moreover, the estimated AUCs were 
significantly higher for the effective im artemether dose compared to the ineffective im 
40 and oral 80 mg/kg artemether doses. In vitro drug assays revealed that DHA reduced 
significantly the viability of F. hepatica flukes, whereas DHA-glucuronide exhibited no 
activity and might not contribute to the drug activity.  
 
To further improve the efficacy and safety of peroxidic drug treatments, we investigated 
the effect of peroxide-triclabendazole combinations against adult and juvenile  
F. hepatica harboured in rats. Negative binomial regressions of worm and egg counts 
were used to analyse dose-response relationships of mono- and combination 
chemotherapy. ED50 values of 113.0, 77.7, 22.9, and 2.7 mg/kg of body weight were 
calculated for monotherapy with artesunate, artemether, OZ78, and triclabendazole, 
respectively, against adult F. hepatica. Encouraging results were achieved using 
peroxides-triclabendazole combinations, since enhanced drug effects compared to 
monotherapy were observed. However, in the case of the artemisinins the observed 
treatment effect depended on the applied triclabendazole dose. Juvenile F. hepatica 
flukes were less sensitive to mono- and combination chemotherapy in vivo and in vitro 
compared to adult flukes. Finally, our chemotherapy studies highlighted a substantial 
loss of precision if egg instead of worm counts were used to estimate dose-response 
relationships.  
 
To sum up, with the help of the developed LC-MS/MS method, we were able to 
determine the PK parameters of artesunate, artemether and their metabolites in sheep, 
which accurately reflected the observed activities against F. hepatica in sheep. The LC-
MS/MS method might be further applied for the analysis of the artemisinins in different 
biological fluids (e.g. bile/urine) and tissues (e.g. liver/flukes). The FLOTAC techniques 
are time efficient and sensitive and hold promise to become a valuable diagnostic tool 
for laboratory work with fascioliasis and probably also for other helminthic diseases. 
Nevertheless, further work is necessary to achieve a better analytical robustness and 
ease of application. Combinations with triclabendazole improved the efficacy of the 
treatments with peroxidic compounds, but further chemotherapy studies against 
triclabendazole resistant F. hepatica strains, studies in ruminants and pharmacokinetic 
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analyses are required to thoroughly evaluate the potential of triclabendazole-peroxide 
combinations.  
In conclusion, the artemisinins are promising lead structures for the development of 
novel peroxidic fasciocidal drugs, because treatment efficacy has been demonstrated 
against adult and juvenile F. hepatica in vitro and in the rat model, in sheep naturally 
infected with F. hepatica and importantly also in rats infected with a triclabendazole 
resistant F. hepatica strain. 
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Zusammenfassung 
 
Die Verursacher der Fasziolose sind die Leberegel Fasciola hepatica sowie Fasciola 
gigantica. Diese parasitäre Erkrankung ist weit verbreitet und besitzt außerdem ein 
breites zoonotisches Reservoir, aus ökonomischer Sicht stellen jedoch die Nutztiere 
Schaf und Rind die wichtigsten Endwirte dar. Seit den 1990er Jahren wird die Fasziolose 
als ein zunehmendes globales Gesundheitsproblem erkannt, schätzungsweise sind 2.4 
bis 17 Millionen Menschen infiziert. Zur Behandlung der Fasziolose wird vor allem 
Triclabendazol empfohlen. Da im Nutztier immer häufiger Behandlungsresistenzen 
vorkommen, werden neue Medikamente dringend benötigt.  
 
Die semisynthetischen Artemisinine und das synthetische Artemisinin-Analogon OZ78, 
ein 1,2,4-Trioxolan, sind peroxidische Verbindungen, die sowohl in vitro wie auch in vivo 
eine vielversprechende Aktivität gegen juvenile und adulte F. hepatica aufweisen. 
Zusätzlich konnte gezeigt werden, dass diese Peroxide auch gegen einen Triclabendazol 
resistenten F. hepatica Stamm aktiv sind.  
 
Im Rahmen dieser Doktorarbeit wurden präklinische Untersuchungen durchgeführt, um 
unser Wissen über das Potenzial der semisynthetischen Artemisinine, Artesunat und 
Artemether zur Behandlung von F. hepatica Infektionen zu erweitern. Darüber hinaus 
wurde die FLOTAC Technik, welche eine neuartige mikroskopische Methode zur 
Detektion und Quantifizierung von F. hepatica Eiern in Stuhlproben darstellt, evaluiert.  
 
Eine sensitive Mikroskopietechnik wurde zur Untersuchung von F. hepatica Infektionen 
in künstlich infizierten Ratten, in natürlichen F. hepatica Infektionen im Schaf und zur 
Analyse des Behandlungserfolgs hinsichtlich der Eierexkretion benötigt. Aus diesem 
Grund haben wir zunächst die Sedimentationstechnik (Referenzmethode) mit der 
FLOTAC Technik zur Detektion und Quantifizierung von F. hepatica Eiern in Stuhlproben 
von infizierten Ratten verglichen. Einen erheblichen Aufwand stellte das Auslesen von 8 
Objektträgern dar, welches durchgeführt werden musste um bei tiefen 
Infektionsintensitäten mit der Sedimentationstechnik eine vergleichbare Sensitivität wie 
nach einer FLOTAC Analyse zu erreichen (85.2% vs. 92.6%). Bei hohen 
Infektionsintensitäten war die Sensitivität für beide Techniken keine Limitation. 
Prinzipiell war die Sedimentationstechnik uniformer und einfacher anzuwenden als die 
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FLOTAC Technik, jedoch war der benötigte Zeitaufwand um eine gute Sensitivität zu 
erreichen viel grösser. Vor allem aus diesem Grund wurde in unserem Labor für 
zukünftige Stuhluntersuchungen FLOTAC und nicht die Sedimentationstechnik 
verwendet. 
 
Die FLOTAC Technik konnte erfolgreich zur Identifikation von natürlich infizierten 
Schafen und zur Quantifizierung der Eierausscheidung verwendet werden. Dies 
ermöglichte die Schafe gemäss der Infektionsintensitäten in ausgeglichene 
Behandlungsgruppen einzuteilen und den Behandlungserfolg anhand der 
Eierausscheidungsmenge abzuschätzen. Die natürlich F. hepatica infizierten Schafe 
wurden mit Einzeldosen von Artesunat oder Artemether mittels unterschiedlicher 
Applikationsarten behandelt. Nach intramuskulärer Verabreichung wiesen beide 
Wirkstoffe gute Aktivitäten auf, wobei viermal weniger Artesunat als Artemether 
benötigt wurde. Nach per oraler Darreichung konnte kein Effekt beobachtet werden. 
Daraufhin wurde die Pharmakokinetik (PK) von Artesunat und Artemether im Schaf 
nach verschiedenen Applikationsarten analysiert, um die beobachteten Aktivitätsdaten 
besser verstehen zu können.  
 
Für die pharmakokinetische Analyse der Artemisinine musste eine Hochleistungs-
flüssigkeitschromatographie Tandem-Massenspektrometrie (LC-MS/MS) Methode zur 
zeitgleichen Detektion und selektiven, akkuraten sowie präzisen Quantifizierung von 
Artesunat, Artemether und deren Metaboliten Dihydroartemisinin (DHA) und 
Dihydroartemisinin-glukuronid (DHA-glukuronid) entwickelt und validiert werden. Der 
Metabolit DHA-glukuronid wurde in diesen PK-studien ebenfalls untersucht, da in einer 
vorausgehenden Analyse grosse DHA-glukuronid Plasmaspiegel detektiert wurden. 
Nach Aufarbeitung der Plasmaproben mittels einer einfachen Proteinpräzipitations-
methode wurde je nach Analyt eine Wiederfindung von 60-80% erreicht. Alle Analyten 
wurden mittels „selected reaction monitoring“ mit einem Übergang von  
m/z 267.4→163.0 im positiv-Modus detektiert. Es konnte gezeigt werden, dass die 
entwickelte Methode die Artemisinine präzise, akkurat und selektiv mit einer 
ungefähren Quantifizierungsgrenze von 10 ng/ml für Artesunat, DHA und DHA-
glukuronid und von 90 ng/ml für Artemether bestimmen kann.  
 
Die Pharmakokinetik von Artesunat nach intramuskulärer Gabe ist durch eine schnelle 
Pharmaka Invasion mit einer Tmax von 15 min sowie einer grossen Pharmaka 
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Disposition, Cmax sowie AUCs, beobachtet für Artesunat und seine Metaboliten, 
charakterisiert. Ein weiteres Charakteristikum der Kinetik ist die schnelle Elimination 
der Pharmaka mit geschätzten Halbwertszeiten von 58-63 min für Artesunat, 94-113 
min für DHA und 89-98 min für das DHA-glukuronid. Artemether hingegen wird nach 
intramuskulärer Darreichung nur langsam und kontinuierlich aus der öligen 
Formulierung freigesetzt, dementsprechend wurden während den 24 Std der 
Probenentnahme mehr oder weniger konstante Artemether und Metaboliten 
Plasmaspiegeln gemessen. Folglich wurden, verglichen mit einer Artesunat i.m. 
Behandlung, nach i.m. Applikation von Artemether niedrigere Cmax aller Analyte 
bestimmt. Anderseits sind die berechneten AUCs der wirkungsvollen Artemether 
Behandlungen (160 mg/kg) vergleichbar mit denjenigen von Artesunat (40 und 60 
mg/kg). Die AUCs, welche nach effektiven Artemether i.m. Behandlungen bestimmt 
wurden, waren signifikant grösser als diejenigen, welche entweder nach wirkungsloser 
intramuskulärer (40 mg/kg) oder per oraler (80 mg/kg) Artemether Gabe gemessen 
wurden. Mittels in vitro Versuchen konnte gezeigt werden, dass DHA gegen  
F. hepatica Egel aktiv ist, während das DHA-glukuronid keine Aktivität besitzt. Aus 
diesem Grund trägt das Glukuronid mit grosser Wahrscheinlichkeit auch nicht zur 
Behandlungswirkung bei.  
 
Um die Effektivität und Verträglichkeit der Behandlungen mit peroxidischen 
Verbindungen zu verbessern, untersuchten wir Peroxid-Triclabendazol Kombinationen 
gegen juvenile und adulte F. hepatica Infektionen in Ratten. Die Analyse der Dosis-
Wirkungs-Beziehung von Mono- und Kombinationstherapien wurde mittels negativ 
binomialer Regression der Wurm- und Eieranzahlen errechnet. Gegen adulte F. hepatica 
Egel wurden ED50 Werte von 113.0, 77.7, 22.9 und 2.7 mg/kg Körpergewicht für 
Artesunat, Artemether, OZ78 und Triclabendazol ermittelt. Die Tatsache, dass verstärkte 
Aktivitäten bei Peroxid-Triclabendazol Kombinationsbehandlungen verglichen zu den 
jeweiligen Monotherapien beobachtet wurden, ist viel versprechend. Jedoch war bei 
Kombinationen aus Artemisininen und Triclabendazol der verstärkte Effekt abhängig 
von der verwendeten Triclabendazol Dosis. Desweiteren wurde beobachtet, dass 
juvenile Würmer im Vergleich zu adulten Würmer weniger deutlich auf Mono- und 
Kombinationstherapien reagierten, sowohl in vitro als auch in vivo. Unsere 
Chemotherapie Studien zeigten ausserdem, dass sich die Präzision von Dosis-Wirkungs-
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Beziehungen basierend auf Berechnungen der Eieranzahlen bedeutend verschlechtert, 
wenn man sie mit Berechnungen basierend auf Wurmanzahlen vergleicht.  
 
Zusammengefasst, ermöglichte uns die entwickelte LC-MS/MS Methode die Bestimmung 
der PK Parameter von Artesunat, Artemether und dessen Metaboliten im Schaf, welche 
die beobachteten Aktivitäten gegen F. hepatica zufriedenstellend reflektierten. 
Zusätzlich könnte diese Methode möglicherweise auch für die Analyse der Artemisinine 
in anderen Körperflüssigkeiten (Galle/Urin) oder Geweben (Leber/Egel) angewendet 
werden. Die Zeiteffizienz und Sensitivität der FLOTAC Technik ist vielversprechend und 
aufgrund dessen könnte diese Technik ein wertvolles diagnostisches Instrument für die 
Arbeit im Labor mit Fasziolose und unter Umständen auch für weitere 
Wurmerkrankungen werden. Jedoch sind zusätzliche Optimierungen der Methode 
notwendig, um dessen Robustheit und Einfachheit in der Handhabung zu verbessern. 
Kombinationen mit Triclabendazol verbesserten die Behandlungseffizienz der 
peroxidischen Verbindungen. Dennoch werden weitere Experimente benötigt, zum 
Beispiel Kombinationsstudien gegen Triclabendazol resistente F. hepatica Stämme 
sowie Studien im natürlichen Endwirt Schaf unterstützt von PK Analysen, um das 
Potenzial dieser Kombinationen voll und ganz abschätzen zu können.  
Schlussfolgernd stellen die Artemisinine vielversprechende Leitstrukturen für die 
Entwicklung von neuartigen peroxidischen Wirkstoffen zur Behandlung der Fasziolose 
dar, da diese Substanzklasse gegen juvenile und adulte Würmer wirkt sowie Aktivitäten 
im Schaf und entscheidend auch in Ratten, infiziert mit einem Triclabendazol resistenten 
F. hepatica Stamm, gezeigt wurden. 
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Table of Abbreviations 
 
AM Artemether 
AS Artesunate 
AUC Area under the plasma concentration time curve 
CAD Collision gas 
CE Collision energy 
Cmax Maximal plasma concentration 
CV Coefficient of variation 
DHA Dihydroartemisinin 
DHA-G Dihydroartemisinin-12-α-o-β-D-glucuronide 
DHA-glucuronide Dihydroartemisinin-12-α-o-β-D-glucuronide 
EBR Egg burden reduction 
EC50/90 Concentration required to kill 50/90% of the parasites 
ED50/90 Doses required to kill 50/90% of the parasites 
ELISA Enzyme-linked immunosorbent assay 
EPG Number of eggs per gram of stool 
ESA Excretory-secretory antigen 
ESI Electrospray ionization  
FEC Faecal egg count 
FECRT Faecal egg count reduction test 
FS Flotation solution 
HPLC High pressure liquid chromatography 
HPLC-ECD High pressure liquid chromatography with electrochemical detection 
IQR Interquartile range 
IS Internal standard 
KW Kruskal-Wallis test 
LC-MS/MS Liquid chromatography tandem mass spectrometry 
LLOQ Lower limit of quantification 
LRS Likelihood ratio statistics 
MW Molecular weight 
NMR Nuclear magnetic resonance 
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NPV Negative predictive value 
NTDs Neglected tropical diseases 
OZ78 Synthetic artemisinin-like compound, 1,2,4-trioxolane 
PCR Polymerase chain reaction 
PEG Polyethylene glycol 
PK Pharmacokinetic 
QC Quality control 
RRE Relative recovery 
RSD Relative standard deviation 
S.g. Specific gravity 
SAR Structure-activity relationships 
SD Standard deviation 
SE Standard error 
SEM Scanning electron microscopy 
SRM Selected reaction monitoring 
t1/2 Elimination half-life 
TEM Transmission electron microscopy 
Tmax Time to achieve maximal plasma concentration 
ULOQ Upper limit of quantification 
USFDA US Food and Drug Administration 
WAAVP World Association for the Advancement of Veterinary Parasitology 
WBR Worm burden reduction 
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General Introduction 
Fascioliasis: Biology, Control and Epidemiology 
 
1 Food-borne Trematodiasis 
 
Food-borne trematodiasis is caused by trematode parasites and belongs to the group of 
neglected tropical diseases (NTDs), a group of diseases which affect primarily poor and 
marginalized people in rural settings of the developing world [1, 2]. Collectively, the 
NTDs cause an estimated global disease burden of more than 50 million disability-
adjusted life years and therefore represent the 4th most important group of infectious 
diseases, behind respiratory infections, HIV, and diarrheal diseases [2, 3]. It is estimated 
that more than 10% of the world’s population is at risk of infection from the major food-
borne trematodes (~750 million people) with at least 40 million infections worldwide 
[4, 5]. Food-borne trematode infections are frequently zoonotic diseases and hence also 
cause a significant veterinary problem and massive economic losses to the agriculture 
sector (see also Section 4.2) [6-8]. 
The trematodes, or flukes, belong to the phylum Platyhelminthes and include 
approximately 70 species, which are known to infect humans via food ingestion [9]. The 
food-borne trematodes are often classified according to the organ the adult worm 
occupies in the mammalian hosts and hence comprise of intestinal (Echinostoma spp., 
Fasciolopsis buski and heterophyids), lung (Paragonimus spp.), and liver (Clonorchis 
sinensis, Opisthorchis viverrini and felineus, and Fasciola gigantica and hepatica) flukes. 
The latter liver fluke, Fasciola hepatica shall be pointed out particularly, since this thesis 
deals exclusively with this parasite [5]. The trematode flukes have various sizes and are 
characterised by a bilaterally symmetrical and dorsoventral flattened anatomy (Fig. 1) 
[10]. Further characteristics are the presence of an oral sucker and often a ventral 
sucker, which allow the worms to attach within the host organism. The flukes are always 
hermaphroditic and exhibit no respiratory and circulatory systems [10]. The tegument, 
a syncytial epithelium, surrounds the trematodes and is associated with nutrient 
absorption, synthesis, secretion, and osmoregulation and possesses additional sensory 
functions [10]. Importantly, it protects the parasite from host detergents (bile acid), 
digestion (enzymes), and immune system [10, 11]. 
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2 Biology and Life-cycle of Fasciola spp 
 
The food-borne trematodes, Fasciola hepatica and F. gigantica infest a broad range of 
animals and accidentally also humans. Farm animals such as sheep and cattle are most 
commonly affected by fascioliasis and act as the main mammalian end hosts. However, 
Fasciola spp. can develop in a variety of animals such as deer, llamas, kangaroos, rabbits, 
beavers and rats, which demonstrates the remarkable capability of the parasite to adapt 
to new hosts [12, 13].  
The life-cycle of F. hepatica is initiated with mature flukes starting to lay eggs (Fig. 2). 
Adult F. hepatica flukes are able to excrete up to 20,000 eggs per day in the biliary ducts 
of their hosts [14]. The eggs are oval in shape with a size of 130-145 μm in length and 
70-90 μm width, and are therefore large compared to the eggs of other trematode 
worms. The yellow-brownish colour and the operculum are further characteristics of  
F. hepatica eggs [10, 14]. The immature F. hepatica eggs migrate through the ductus 
choledochus into the duodenum and are released in the environment with faeces (A). 
 
Figure 1. Food-borne trematodes (Swiss Tropical and Public Health Institute archive, Joachim Pelikan) 
 
(A) Fasciola hepatica, (B) Fasciolopsis buski, (C) Clonorchis sinensis, (D) Opisthorchis viverrini. 
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Approximately 5,000 eggs per gram faeces (EPG) can be excreted in heavy infections of 
humans as has been observed in hyperendemic areas [12, 15, 16]. Embryonation occurs 
outside the host and especially humidity, temperature and oxygen tension influence its 
the development [14]. The F. hepatica eggs hatch within 2 to 3 weeks and release free-
swimming miracidia, which either invade molluscan intermediate hosts, typically 
Galba/Lymnaea truncatula, or die within 24 hours [13, 14] (B). Miracidia are strongly 
phototropic and a positive chemotactic reaction to L. truncatula occurs up to a distance 
of 15 cm [14, 17]. The miracidia multiply asexually within the snail and develop during 
4-7 weeks into sporocysts, rediae, and finally cercariae [12, 14] (C). A snail infected with 
a single miracidium produces around 4,000 free-swimming cercariae [18]. The tadpole-
like cercariae (250-300 μm) attach to freshwater vegetation and encyst to 
metacercariae, which stay infectious for over a month, depending on environmental 
conditions [14] (D). Mammalians get infected by ingesting metacercariae through 
consumption of aquatic vegetables or contaminated water [19] (E). The F. hepatica 
metacercariae excyst in the small intestine, penetrate the intestinal wall, burrow 
through liver parenchyma within 5 to 6 weeks and finally lodge in the bile ducts for 
years. The life span of F. hepatica flukes is an estimated 9-13 years in humans, 1-2 years 
in cattle, and up to 20 years in sheep [10, 12, 14]. Fully-grown F. hepatica (Fig. 1A) 
measure up to 20 to 50 mm in length whereas F. gigantica can be as large as 75 mm in 
length [20, 21]. Finally, the life cycle is completed approximately 8 weeks post infection, 
when mature F. hepatica flukes start excreting eggs in the bile [14] (A).  
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Figure 2. The Life-cycle of F. hepatica. Adapted from [10, 22, 23] 
 
(A) End host infected with F. hepatica, (B) Excretion of eggs with faeces and miracidia 
hatching, (C) Infection of the molluscan intermediate host, (D) Release of cercariae and 
encystment to infectious metacercariae, (E) Infection of the end host by consumption of 
contaminated aquatic plants or water with metacercariae. 
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3 Pathogenesis and Clinical Aspects of Fascioliasis 
 
Pathological studies of fascioliasis were mostly accomplished in experimental animals 
such as rats or sheep and not humans, since there are few opportunities for post-
mortem examinations with human subjects. However, the existing data suggests that 
human fascioliasis parallels that in animals and the maturity rate of F. hepatica in sheep 
is similar to that in humans [13, 24, 25]. 
It is conceivable that the severity of the disease correlates with the number of parasites 
per host. Therefore, disease severity and symptoms can vary and range from 
asymptomatic to highly pathogenic and debilitating symptoms [24, 26]. Fascioliasis can 
be grossly subdivided into two pathogenic phases: the acute (parenchymal) and chronic 
(biliary) phase. The former occurs during the migration of the juvenile flukes through 
the liver parenchyma, whereas the latter arises when mature flukes reside in the bile 
ducts [24, 26]. Mammalians may be simultaneously infected with F. hepatica of different 
stages and present a complex pathology. In the case of human fascioliasis, commonly 
only a few parasites reach the bile ducts, since humans are not the natural end host [24].  
 
3.1 Acute Fascioliasis  
 
Acute fascioliasis starts once juvenile F. hepatica flukes have reached the host’s liver 
(~90 h post-infection). The penetration through the intestinal wall is not associated 
with clinical signs and the appearance of the first symptoms can take a few days to a few 
months (= incubation phase) [24, 26]. Juvenile flukes digest hepatic tissue during the 
liver migration stage, which causes haemorrhage and inflammation. Necrosis, fibrosis, 
and even migration tracts of flukes can be detected in a histological liver examination 
(Fig. 3). Unspecific symptoms such as fever, weakness due to anaemia, abdominal pain, 
and gastrointestinal disturbance arise in the acute phase of infection [26, 27]. Hepatic 
damage potentially leads to hepatosplenomegaly, ascites, and jaundice. Sudden death 
can occur, in particular in sheep and goats, due to extensive blood loss caused by liver 
haemorrhage, liver failure, or secondary infections with Clostridium novyi (= black 
disease) [24, 26, 28]. However, black disease infections are uncommon today due to 
effective vaccination [24]. The mortality due to Fasciola spp. infections is low in humans 
and case reports suggest that children are more often affected [25-27].  
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 In addition, ectopic fascioliasis can be observed if the parasites deviate during 
migration and enter other organs such as the diaphragm, lung, or intestine. 
Inflammatory respiratory lesions including pneumonia and fibrous pleuritis are 
regularly recorded and the pathology is more significant in heavy infections [24, 26, 29].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.2  Chronic Fascioliasis  
 
In the chronic phase of the disease, the parasites have entered the bile-ducts and have 
started to lay eggs. Fibrosis, hyperplasia, dilatation, calcification, and thickening of the 
bile ducts and gallbladder are characteristics of this stage (Fig. 3) [26, 27]. Periods of 
indistinguishable gastrointestinal disorders or even no symptoms are present in human 
chronic fascioliasis (= latent phase). Nevertheless, the latent phase is intermitted by 
obstructive periods, where parasites or debris block the bile ducts. Severe complications 
such as cholestatic hepatitis, cholecystitis, cholangitis, choledocho- and cholecysto-
lithiasis, acute pancreatitis, and bacterial superinfections might be monitored [26]. 
Observed consequences may include biliary colic pain, fever, diarrhoea due to fatty food 
intolerance, pruritus, jaundice, and anaemia [26].  
F. hepatica infections in farm animals might result in severe anaemia, which 
considerably affects the morbidity and mortality of the disease. For instance, it has been 
estimated that one fluke is responsible for 0.2-0.5 ml blood lost per day [24, 30, 31]. In 
 
Figure 3. Pathological picture of fascioliasis. 
 
(A) Infected sheep liver, (B) Calcification and thickening of a cattle’s bile 
duct infected with F. hepatica (C) Rat experimentally infected with  
F. hepatica showing liver fibrosis, necrotic liver tissue, and dilatation of the 
bile duct, (D) Healthy rat liver and bile. 
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the chronic phase, sheep and cattle might develop oedema under the jaw (“bottle jaw”) 
[28]. Inappetence and reduced feed conversion compromise weight gain and wool 
growth, hence economic loss is prominent with fascioliasis (Section 4.2) [24].  
 
 
4  Epidemiology of Human and Veterinary Fascioliasis 
 
As mentioned, fascioliasis is on the one hand a disease of great veterinary importance 
and on the other hand, a neglected human disease. Therefore, both epidemiological 
aspects of the disease shall be introduced here. 
 
4.1 Human Fascioliasis 
 
Human infections are usually prevalent in areas where veterinary fascioliasis is 
endemic, because wild and farm animals are the major reservoir of Fasciola spp. and 
contribute considerably to worldwide dissemination as well as to local transmission of 
the disease [12]. However, it seems that a high prevalence of fascioliasis in animals is 
not directly related to increased numbers of cases in human [32]. Instead, 
environmental factors, human habits and especially eating behaviour influence the 
human infection rate [20].  
F. hepatica and F. gigantica display a remarkably large global distribution (Fig. 4), with 
human infections being reported from 51 countries in five continents [33, 34]. 
Distribution of F. gigantica is more limited than that of F. hepatica and is restricted to 
Africa, Asia, Middle East, and Eastern Europe (Fig. 4) [35]. Recent studies have estimated 
that 90 up to 180 million people are at risk of Fasciola spp. infections and between 2.4 
and 17 million individuals are infected worldwide [4, 19, 36]. Nevertheless, the true 
number of Fasciola infections might be considerably higher [34], since recent outbreaks 
were not considered in these estimates, not all countries have reporting systems, and 
infections might be unrecognized due to the potential asymptomatic course of the 
disease. Human fascioliasis is of particular importance in the Andean countries Peru and 
Bolivia, Egypt, the Islamic Republic of Iran, Cuba, Vietnam, and the Western European 
countries Portugal, Spain, and France (Fig. 4) [4, 26, 37]. The highest prevalences and 
intensities of human fascioliasis were observed in the Northern Bolivia Altiplano, with 
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more than 40% of infected individuals in certain communities [12, 13]. For example, it 
has been estimated that in Bolivia as many as 360,000 humans are infected with  
F. hepatica [4]. In addition, 830,000 individuals are potentially infected with fascioliasis 
in the Nile Delta region of Egypt [4], with observed high mean prevalence of 12.8% (5.2-
19.0%) in some villages [13, 38]. In comparison, human fluke infections are rare in 
Europe, however regular outbreaks of the disease occur in France, Spain, and Portugal, 
causing about 50-100 infections per year [12].  
Most of the reported cases of human fascioliasis are due to infections of F. hepatica and 
only a few reports e.g. from Vietnam, Egypt, and Thailand indicate F. gigantica as an 
agent of human fascioliasis [8, 12, 39]. 
The distribution pattern of fascioliasis has a patchy character, because it depends on 
general physiographic and climatic conditions as well as the dissemination of the 
intermediate snail host populations in freshwater bodies [32]. The global distribution of 
human fascioliasis on a country level is depicted in Fig. 4. Note that, due to reasons 
highlighted above, the disease distribution is not uniform within these countries. 
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Figure 4. Estimated distribution of human and veterinary fascioliasis adapted from  [35, 37] 
 
Estimates of infected individuals worldwide [4] Distribution of Fasciola spp. [35] 
 
  Andean countries 
Peru: 742,000 
Bolivia: 360,000 
Ecuador: 20,000 
  Caribbean countries 
Cuba: n.a. 
  Western Europe  
Portugal: 267,000 
Spain: 1,000 
France: n.a. 
 
  Africa 
Egypt: 830,000 
  Middle East 
Iran: 10,000 
  Asia  
China: 160,000 
Vietnam: n.a. 
 
 
 
 
 Distribution of F. hepatica,  
 Distribution of F. gigantica 
 Overlapping regions, where both 
Fasciola spp. may be present  
 
 
 
 
 
n.a. = not available 
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4.2 Veterinary Fascioliasis  
 
Fasciola spp. are present on every continent on earth, except Antarctica and are able to 
live in areas from below sea level in the Caspian region up to a very high altitude of 
4,200 m at the Paso del Condor in Venezuela. Hence, fascioliasis is the vector-borne 
disease with the greatest latitudinal, longitudinal and altitudinal distribution known 
(Fig. 4) [33, 34]. Livestock animals such as sheep, cattle, and buffalo are the most 
important end hosts from an ecological point of view [35]. It is challenging to provide a 
countrywide overview of fascioliasis in livestock, since numerous countries and animals 
are affected. Importantly, fascioliasis due to F. hepatica or F. gigantica is of veterinary 
significance and it appears to be independent of the country’s wealth, since high 
prevalences were noted from all over the world. For instance, the following prevalences 
of Fasciola spp. infections in farm animals were recorded: USA; 5.9-68%, Switzerland; 
18%, Spain; 29.5%, Chile; up to 94%, UK; 10%, New Zealand; 8.5%, Thailand; 47.1%, 
and Nigeria; 43% [35, 40]. Taken as a whole, it has been estimated that more than 250 
million sheep and 300 million cattle are infected with F. hepatica worldwide [12, 41]. 
Hence, infections with Fasciola spp. cause an economic loss to the agriculture sector due 
to reductions in weight gain, milk yield and fertility and in the case of sheep, a decrease 
in wool production [35, 42, 43]. A recent estimate calculated a median financial loss of 
€299 per year per infected dairy cattle in Switzerland, where this loss arises mostly 
from reduced milk yield and fertility and less so from reduced meat production and 
treatment costs [42]. Overall, fascioliasis causes an estimated financial loss of more than 
US$ 3 billion per year to the agriculture sector worldwide [8, 12].  
 
5 Diagnosis of Fascioliasis  
 
Diagnostic tools build the basis for successful prevention and control of infection 
diseases including fascioliasis. First and foremost, an accurate diagnostic method is 
obviously needed to identify infected individuals in a population and thus to enable 
proper intervention strategies, prevalence records, and ultimately accurate estimates of 
the global disease burden. In addition, a sensitive and specific diagnostic method is 
essential for evaluating treatment outcomes and community effectiveness of 
interventions, as well as verifying local disease eliminations and early detection of 
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reappearances [44]. Direct parasitological diagnostics, immunodiagnostics, molecular 
diagnostics, and imaging techniques are the main ante-mortem tools to diagnose 
Fasciola spp. infections [10].  
Imaging techniques such as ultrasound, computer tomography, and magnetic resonance 
imaging can reveal the hepatobiliary damages (biliary stones, fibrosis, and calcifications) 
caused by fascioliasis [10, 45]. However, these techniques alone are not sufficiently 
sensitive for the diagnosis (<15%) [26], since the apparent pathological picture is not 
specific for fascioliasis. However, these imaging devices might be important to exclude 
secondary damages and to survey the healing process [25].  
Immunodiagnostics, in particular enzyme-linked immunosorbent assays (ELISA), are 
applicable as serological and coprological indirect tests. The former detects circulating 
IgG antibodies elicited by infected individuals against fluke antigens, such as cystein 
proteinase (Fas2) and cathepsin L1 (CL1), whereas the latter detects antigen in stool 
samples including Fasciola excretory-secretory antigens (FES-Ag) [26, 46, 47]. These 
tests are characterised by a high diagnostic sensitivity and hence are able to identify 
low-infection intensities. In addition, prepatent infections (~1-2 week post infection) 
and ectopic fascioliasis can be detected [13, 26]. However, there are difficulties to 
evaluate treatment outcome with ELISA tests, because circulating antibodies might not 
disappear immediately post treatment [48]. Furthermore, cross-reactivity with 
infections of other trematode species can arise [49].  
In contrast to immunodiagnostics and copromicroscopy, polymerase chain reaction 
based methods (PCR) allow for a safe differential diagnosis of F. hepatica and F. 
gigantica infections [13]. This is important because differentiation between eggs from 
Fasciola spp., Fasciolopsis, and echinostomes is difficult by microscopy [27]. Moreover, 
PCR can be applied to detect Fasciola spp. infections within the snail population [50]. 
In terms of direct parasitological diagnostics, F. hepatica eggs are detected in stools 
(=copromicroscopy), duodenal fluid, or bile aspirates. Traditionally, the 
copromicroscopic techniques including the Kato-Katz method and the sedimentation 
method are used to analyse F. hepatica eggs in stools [51, 52]. These diagnostic 
approaches allow for estimating infection intensity and treatment outcome. 
Furthermore, they are applied to evaluate the efficacy of anthelmintics in ruminants 
[53]. Coprodiagnostic methods have the advantage of being cost-effective and relatively 
easy to perform, which render them widely applicable in resource-constrained settings 
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[26]. However, only chronic F. hepatica infections can be diagnosed, since eggs are 
excreted only from mature worms and hence ectopic fascioliasis and acute infections  
(~ first 3 months) remain undiscovered [26]. Coprodiagnostic methods are sufficiently 
sensitive in detecting moderate and high Fasciola spp. infection intensities, but the 
methods lack sensitivity for detecting low-intensity infections. Still, repeated sampling 
can improve sensitivity significantly [26, 54].  
To improve the sensitivity of traditional coprodiagnostic methods, a series of novel 
multivalent faecal egg count (FEC) techniques, the FLOTAC techniques, have recently 
been developed for the qualitative and quantitative diagnosis of human and veterinary 
helminth infections [55]. The FLOTAC apparatus (Fig. 5) is the core of these various 
techniques. This device consists of two flotation chambers, which can be loaded with  
5 ml faecal sample suspensions each. The principle is that parasitic elements, such as 
eggs, float on top of the chamber, whereas faecal debris sediment during centrifugation. 
Subsequent translation of the apical portion of the floating suspension separates the 
eggs from debris. The degree of parasitic element flotation depends on the parasite and 
host species as well as the applied flotation solution. Therefore, the most suitable 
flotation solution is selected in a calibration step, among a panel of nine flotation 
solutions with specific gravities (s.g.) ranging from 1.2 to 1.45 [55]. The great advantage 
of these techniques is that a single FLOTAC uses up to 1 gram of stool per analysis with a 
sensitivity of 1 egg per gram, whereas a single Kato-Katz analyses only 41.7 mg of stool 
[55]. For more details, the reader is referred to chapter 2.  
 
 
Figure 5. An illustration of the FLOTAC techniques adapted from [55] 
 
(A) Photography of the FLOTAC apparatus  
(B) Cross-section of the FLOTAC
 
apparatus 
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6 Control Strategies against Fascioliasis 
 
Fasciola spp. exhibits the remarkable ability to adapt to a broad variety of end hosts, 
ranking from humans to livestock and various wild animals, which collectively build a 
major reservoir for the parasite and contribute to the dissemination of the disease [12].  
Therefore, an effective control strategy against fascioliasis is complex and includes both 
different mammal end hosts as well as molluscan intermediate hosts. A universal 
concept may not available, since fascioliasis affects too many various regions with 
diverse circumstances such as different climatic conditions (temperature, humidity), 
dissimilarly developed sanitation, variable human behaviour, and diverse zoonotic 
reservoirs.  
Complete eradication of fascioliasis appears unlikely at the moment, because no highly 
active vaccines are available [56]. To date, there are only experimental vaccine 
candidates available, which provide moderate protection efficacy [12, 56]. However, it 
has been shown that the prevalence of fascioliasis can be diminished with adequate 
control strategies, including treatment with anthelmintics (section 7), molluscicides, 
grazing management, changing of human behaviour, community-based education, and 
improved access to adequate sanitation [10, 28, 35]. 
Human fascioliasis would be preventable if only thoroughly washed vegetables and 
cooked water are consumed as well as kitchen utensils are carefully sanitized. 
Nevertheless, the implementation appears difficult, because changing human behaviour 
is not easy, and the potential contamination sources are diverse and differentiate 
between regions. For instance, consumption of watercress, spearmint, lettuce, alfalfa 
juice, contaminated water (floating metacercariae), and raw liver containing juvenile 
worms are potential risk factors of human fascioliasis [20, 57-59]. However, 
improvements in sanitation such as the construction of an appropriate filtration system 
of piped water, have decreased human infections in some Nile delta areas [20]. 
Community-based education on aspects of parasite transmission such as the importance 
of separating animals from areas where food is grown can directly reduce cases of 
human fascioliasis [12].  
Drug treatment programs should initially emphasize children in high-risk areas, because 
highest prevalence is present in children between 8 and 11 years old [12, 60]. Regular 
treatment of livestock animals with fasciocidals covering juvenile and adult flukes will 
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reduce infection intensity over time. For instance, chemotherapy reduced the prevalence 
of F. hepatica infections by up to 75% on some Irish farms and from 49% down to 1% on 
farms in Scotland [35, 61, 62]. The chosen treatment schedule depends on seasonal 
transmission dynamics and hence schedules vary from single annual treatment up to 
multiple (4-5) treatments per year. However, a complete elimination was not realizable 
using anthelmintics only, probably because of the broad wild animal reservoir of 
fascioliasis [35].  
A further strategy includes control of the intermediate molluscan host. Molluscicides 
such as niclosamide were successfully used to control snail populations, but this 
approach might not be suitable from an ecological point of view, because of the risk of 
environmental impairment. Infection control might be attained with environmentally 
friendly approaches such as the use of natural molluscicides (Eucalyptus and 
Euphorbiales spp.), predator species (goose and ducks), competitor molluscs (non-host 
species of snails: zonitoides nitidus), and draining or fencing-off wet areas on pasture 
[35].  
Taking all strategies into account, what is really important is to keep in mind both 
human and animal infections and choose the strategies appropriate for each region. 
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7 Treatment Options: Marketed and Experimental Drugs  
 
7.1 Marketed Drugs 
 
No new fasciocidals have been introduced on the market since the 1980s [63]. To date, 
the available drugs for veterinary use can be classified into the following five main 
chemical groupings (Fig. 6 A-E): halogenated phenols, salicylanilides, benzimidazoles, 
sulphonamides, and phenoxyalkanes [63]. Among all fasciocidals only the 
benzimidazole, triclabendazole (Egaten®) is recommended for human use [26, 64]. In 
addition, it is registered in only four countries worldwide [64]. In the past, bithionol was 
applied in humans, but it is no longer recommended, because of its prolonged treatment 
course (50 mg/kg/day for 20-30 days) with moderate to low cure rates and its frequent 
gastrointestinal adverse drug events [26, 64]. For comparison, a single oral dose of 10 
mg/kg triclabendazole achieves an average worm burden reduction of more than 90% 
against all stages of F. hepatica. This broad activity of triclabendazole is unique, since no 
other fasciocidals show a similar broad efficacy and frequently lack activity against 
juvenile worms (Table 1). For instance, the activity of the related benzimidazole 
albendazole is also restricted to mature worms and multiple doses are needed to 
achieve a good response [63].  
 
Table 1. Estimated stage activity of different fasciocidal drugs at recommended dose rates 
against F. hepatica in sheep.  No activity   Moderate activity   High activity 
adapted from [63] table 2 
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Triclabendazole lacks activity against nematodes and cestodes in contrast to other 
benzimidazoles [63, 65]. Higher dosages of triclabendazole showed activity against 
different Paragonimus spp. (= lung fluke) [64]. A disadvantage of triclabendazole is that 
it accumulates in milk and therefore cannot be applied to lactating cows [28, 66]. 
Triclabendazole is extensively metabolized in vivo to triclabendazole-sulfoxide and -
sulfone. Triclabendazole-sulfoxide is the main active component of triclabendazole. It 
has been suggested that triclabendazole-sulfone might also contribute to the fasciocidal 
activity [67]. The high treatment potency of triclabendazole might be of particular value 
in resource-constrained settings, where drug accessibility is limited and a simple 
treatment schedule is needed for a successful intervention. However, it is frightening 
that triclabendazole resistance has been documented from Australian sheep farms since 
the mid-1990s and thereafter also from western European countries including the 
United Kingdom, Netherlands, and Spain and recently also from Latin America in 
Argentina [67-69]. The mode of resistance is not yet fully understood; altered 
triclabendazole uptake and metabolism of resistant F. hepatica isolates are to date the 
most convincing mechanisms. In addition, resistant F. hepatica strains were observed 
against salicylanilides, closantel and rafoxanide [41, 63]. Fortunately, until now there is 
no evidence of drug resistance in human F. hepatica infections. Nevertheless, the risk is 
present, since human and veterinary fascioliasis are interlinked. 
To conclude, there is a strong need of back-up drugs or effective drug combinations to 
overcome the dilemma of drug resistance and the narrow arsenal of potent fasciocidals.  
 
7.2 Drug Screening Methods against Fasciola hepatica 
 
It is not possible so far to cultivate F. hepatica in vitro throughout the entire life cycle 
[23], and consequently laboratory animals are indispensable for drug screening against 
fascioliasis. Therefore, ethical considerations such as replace, reduce and refine life-
animal (3R) have to be integrated in the drug screening process [70]. As a rule, the most 
effective drug candidates should be evaluated first in vitro before testing the in vivo 
activity in rodents.  
In vitro screening of F. hepatica can be accomplished against newly excysted 
metacercariae obtained from infected snails or against fluke’s isolates from the liver and 
bile of experimentally or naturally infected animals [23]. F. hepatica infections of sheep 
and cattle are frequent in endemic countries (Section 4.2) and therefore parasite 
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material can be obtained from animals slaughtered in abattoirs [23, 71]. The drug effect 
on the viability of newly excysted metacercariae or of adult and juvenile flukes is 
commonly evaluated using laborious phenotype-based viability assay, where the 
motility of the flukes is monitored [23]. Calorimetric and colorimetric viability assays 
hold promise to become a more efficient alternative to phenotype-based assays, which 
enables an easier standardisation of the experiments [23, 72].  
After in vitro screening, the most prominent drug candidates are selected for further 
investigations in vivo. Therefore, rats are infected with 20-30 metacercariae by oral 
gavage and treated 3-5 weeks (juvenile flukes) or 8-12 weeks (adult flukes) post 
infection. The drug activity can be evaluated one week post-treatment by analysing the 
worm burden reduction of treated compared to untreated controls [23]. The efficacy of 
drug candidates, which showed promising activity in the rat model, can be further 
evaluated in larger animals such as naturally or experimentally F. hepatica infected 
sheep. For more detail, the reader is referred to chapter 4.  
Promising in vitro activities of lead compounds can sometimes not be translated to an  
in vivo efficacy, since pharmacokinetic properties of the molecules including poor 
bioavailability, extensive metabolism, and fast drug clearance might avert a potential 
effect [73]. Therefore, the analysis of the pharmacokinetic parameters of drug 
candidates is essential to understand a potential in vivo ineffectiveness and additionally 
important to improve the pharmacokinetic properties of second generation analogues. 
The reader is referred to chapter 5 and 6.  
 
7.3 Experimental Drugs - Artemisinins 
 
Artemisinin (qinghaosu), a secondary plant compound of the herb Artemisia annua 
(Chinese wormwood), is highly effective against Plasmodia spp. [74]. In 1971, the 
antimalarial activity of A. annua extracts was discovered and the chemical structure of 
the active constituent artemisinin was identified in the late 1970s [75]. Artemisinin has 
a sesquiterpene lactone scaffold that contains a peroxide bond in a unique 1,2,4, 
trioxane heterocycle (Fig. 6 F & G). Semi-synthetic derivatives such as artemether and 
artesunate were developed, because artemisinin itself has biopharmaceutical 
shortcomings including poor bioavailability and low solubility in water and oil [76]. The 
methyl ether derivative artemether (Fig. 6 F) is characterised by a stronger 
antiplasmodial activity than artemisinin. Furthermore, artemether can be applied orally 
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or intramuscularly in an oil-based drug formulation. Artesunate (Fig. 6 G) is soluble in 
water because of its succinate functional grouping, and can be applied intravenously and 
is therefore indispensable for the treatment of severe malaria [77].  
Even though the semisynthetic artemisinins possess better biopharmaceutical 
properties than artemisinin itself, shortcomings including low bioavailability and short 
half-life are still apparent. Furthermore, there is the disadvantage of growing Artemisia 
annua as a starting material [77]. Hence, totally synthetic artemisinin-like peroxides 
such as 1,2,4-trioxolanes (=OZ compounds, Fig. 6 H) were produced which showed 
excellent antimalarial activity and improved biopharmaceutical proprieties [78].  
The antiparasitic activity of the semisynthetic and synthetic artemisinins are not 
restricted to Plasmodia spp, given that Schistosoma spp. and several other food-borne 
trematodes are also affected by this compound class [37, 79]. The discovery of the 
trematocidal effect of artemisinin occurred in the early 1980s in China, where the 
trematocidal properties were first recorded for Schistosoma japonicum and Clonorchis 
sinensis [37, 80]. Later, further promising in vitro and in vivo activities of the 
semisynthetic and synthetic artemisinins (OZ78) were recorded against several 
Schistosoma spp. and major food-borne trematodes including E. caproni, O. viverini, and 
most important for this work F. hepatica [37]. 
Artesunate and artemether kill F. hepatica flukes in vitro, and damage the tegument and 
the gastrointestinal system of the parasite [81, 82]. The mode of action of the 
artemisinins against Fasciola spp. has not been elucidated. However, the presence of 
haemin in culture medium resulted in an increased in vitro activity of the artemisinins, 
which suggests that iron plays a role in the cleavage of the peroxide bond and the 
generation of free radicals, a mechanism similar to one of the proposed mechanisms of 
action of artemisinin against Plasmodium [81, 83]. Besides the in vitro activity, 
artesunate and artemether were active against F. hepatica in experimentally infected 
rats [84]. For more details, the reader is referred to chapter 3. It is promising that 
artemether and the synthetic artemisinin, OZ78, were active against triclabendazole 
resistant F. hepatica isolates in the rat model [85]. In light of the veterinary importance 
of fascioliasis, the activity of artemether was assessed in sheep harboring natural  
F. hepatica infections. Treatment outcome relied on the route of drug administration and 
the applied dosage. On the one hand artemether achieved good worm and egg burden 
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reductions >90% at 160 mg/kg given intramuscularly, while a 40 mg/kg dose and oral 
treatment lacked activity [86]. More details are given in chapter 6.  
Finally, there is evidence that artesunate may also play a role in treatment of acute 
human fascioliasis [87]. 
 
 
 
 
Figure 6. Chemical structure of fasciocidal marketed drugs (A-E) and experimental 
fasciocidals (F-H). adapted from [37, 88] 
 
(A) Triclabendazole, (B) Bithionol, (C) Diamphenethide, (D) Clorsulon, (E) Closantel,  
(F) Artemether, (G) Artesunate, and (G) OZ 78 
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8 Aim and Objectives 
 
There is a pressing need for discovery and development of novel drugs against 
fascioliasis, since to date no vaccine is available for the prevention of the disease, only a 
single drug, triclabendazole is recommended for treatment of human fascioliasis, and 
moreover triclabendazole resistance is a well-known global problem in veterinary 
medicine.  
 
The following 5 objectives were accomplished to further strengthen our knowledge 
about treatment and diagnosis of fascioliasis. 
 
1. To compare the sedimentation and FLOTAC techniques for the detection and 
quantification of F. hepatica eggs in rats (chapter 2). 
 
2. To assess the potential of triclabendazole-peroxidic drug combination therapies in  
F. hepatica infected rats (chapter 3). 
 
3. To study the anthelmintic activity of artesunate against F. hepatica in naturally 
infected sheep (chapter 4). 
 
4. To develop and validate a sensitive and selective LC-MS/MS method for the 
simultaneous analysis of artemether, artesunate, and their major metabolites for the 
prospective determination of pharmacokinetic parameters (chapter 5). 
 
5. To analyse pharmacokinetic parameters of artemether and artesunate in sheep 
naturally infected with F. hepatica (chapter 6). 
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General Discussion 
 
Rationale, Objectives and Aim of the Present Thesis 
 
Fascioliasis has a cosmopolitan distribution, a huge veterinary impact, and since the 
1990s, it has been recognized as an increasing global public health problem [1, 2]. 
Nonetheless, not many people are aware of this neglected tropical disease and only a 
few institutions and companies are interested in research of this parasitic disease [3]. 
Consequently, no novel fasciocidals have been registered on the market since the 1980s 
and as a result, the drug arsenal is small with only one drug, triclabendazole, 
recommended for human use, which is licensed in only four countries worldwide [4-6]. 
To make matters worse triclabendazole resistance is a spreading problem in livestock 
and there are no vaccines available for disease control [7, 8]. To counteract this 
deficiency, novel drugs or drug combinations against fascioliasis need to be discovered 
and developed urgently.  
 
In my PhD thesis, I tackled preclinical investigations in order to treat Fasciola hepatica 
infections with semisynthetic artemisinins, and furthermore evaluated the FLOTAC 
techniques, an innovative copromicroscopic tool for diagnosis of fascioliasis and 
quantification of treatment outcome. The finding that peroxidic drugs, including the 
semisynthetic artemisinin derivatives and the artemisinin-like synthetic 1,2,4-trioxolane 
OZ78, exhibit promising fasciocidal activity preceded this project and was the starting 
point of this thesis. In brief, it was described that artemether, artesunate, and OZ78 kill 
F. hepatica flukes in vitro and possess in vivo activity against adult and juvenile  
F. hepatica in experimentally infected rats [9, 10]. In addition, it was shown that 
artemether and OZ78 are effective against a triclabendazole resistant F. hepatica strain 
in the rat model [11]. Finally, the efficacy of artemether was assessed in sheep naturally 
infected with F. hepatica: intramuscular treatments were effective while oral 
applications lacked activity [12].  
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The aim of the present thesis was to advance our knowledge of the fasciocidal properties 
of the artemisinins by means of preclinical investigations including pharmacokinetics, 
further activity studies in ruminants, and combination therapies. The work conducted 
can be divided in two main parts and shall be summarized briefly (chapter 2-6).  
 
First, since a sensitive, accurate, and user-friendly tool was needed for the detection and 
quantification of F. hepatica eggs in our chemotherapy studies (chapter 3/4), we 
compared the sedimentation technique, which is considered as the reference 
coprodiagnostic method of F. hepatica infections, with the recently developed and 
promising FLOTAC techniques (chapter 2). Copromicroscopy was also used to identify 
naturally infected sheep, to allocate the sheep in treatment groups according to their  
F. hepatica egg count, to confirm the experimental infections in rats and finally to 
estimate the treatment effect on egg excretion (chapter 3/4).  
Second, we observed large differences in treatment outcomes in sheep naturally infected 
with F. hepatica. While orally applied artemether lacked activity and high doses of 
intramuscular artemether were needed to obtain good activity [12], intramuscular 
artesunate revealed a high treatment efficacy with a fourth of the used effective 
artemether dose. This result is different from the observations in rats (chapter 3/4).  For 
this reason, we conducted pharmacokinetic studies of the artemisinin derivatives in 
sheep in order to obtain explanations for the diverse treatment outcomes following 
different routes of application and artemisinin derivatives (chapter 6). In a first step, an 
appropriate analytical method, in our case a liquid chromatography tandem mass 
spectrometry method (LC-MS/MS), had to be developed and validated, since drug and 
metabolite concentrations have to be quantified simultaneously, accurately, precisely, 
and selectively in sheep plasma for the later pharmacokinetic application (chapter 5).  
 
The interrelation of the covered thesis objectives in the drug development process of 
fasciocidal compounds is depicted in Figure 1. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 1. Drug development process of fasciocidal compounds. Adapted from [3, 13, 14] 
   
  PD: Pharmacodynamic, PK: Pharmacokinetic, LADMET: Drug Liberation, Absorption, Distribution, Metabolism, Excretion, Toxicity 
 (№): Thesis objectives 1-5 (chapter 1, section 8) 
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The results generated in these five objectives present my thesis, which will be discussed 
in a general manner and put into a wider context in the following pages. “Objective 
specific” issues have already been discussed in the last section of each chapter and 
therefore they will be taken into account in only a few instances to avoid unnecessary 
repetitions. Based on the obtained results and my own experience, novel ideas, open 
questions, different approaches, future perspectives, and my personal opinion will be 
considered in this general discussion. The following four topics have been chosen for a 
more detailed discussion. 
 
(1) Further thoughts in copromicroscopic techniques with particular emphasis on the 
FLOTAC techniques.  
 
(2) The way forward to evaluate drug activity against F. hepatica. Ethical and 
methodological considerations. 
 
(3) Improvement of the LC-MS/MS method for artemisinins quantification 
 
(4) Potential and limitations of the artemisinins for treatment of fascioliasis 
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1 Further Thoughts about the FLOTAC Techniques  
 
An appropriate copromicroscopic technique was required to verify the experimental  
F. hepatica infections in rats and to estimate the egg burden reduction after treatment in 
the combination chemotherapy study. Therefore, we compared the sedimentation and 
FLOTAC techniques in terms of sensitivity, faecal egg count (FEC), and feasibility. In 
brief, the sedimentation technique needed a rigorous reading effort with 8 slides 
examined to achieve a comparable sensitivity to a single FLOTAC in rats characterised 
by low infection intensities (85.2% vs. 92.6%). Sensitivity was not an issue for both 
techniques analysing high infection intensities. Interestingly, significantly higher mean 
FECs were determined with the sedimentation technique. Although the FLOTAC 
preparation is laborious, the reading effort needed to obtain a good sensitivity is lower 
than for the sedimentation technique and therefore FLOTAC is more time-efficient. So 
that the reader can get an idea of what time-efficient means; without exaggeration, it 
was possible to perform 32 FLOTAC analyses a day, whereas 8 analyses with the 
sedimentation technique with 8 slides examined each, filled a working day. For this 
reason FLOTAC, and not the sedimentation technique, was chosen for the future 
copromicroscopic measurements carried out in our laboratories.  
 
As described in chapter 2, several studies in humans and animals showed that FLOTAC 
possesses an advantageous sensitivity compared to various other coprodiagnostic 
techniques including Kato-Katz thick smear, ether-based concentration technique, 
McMaster, and parasep solvent free technique [15-18]. However, the advantages 
observed with FLOTAC depend on the parasite species of investigation and also on the 
individual host organism. For example, new studies showed that the Koga agar plate 
method and the repeated adhesive tape test are not replaceable by FLOTAC, and remain 
the method of choice for the diagnosis of Strongyloides stercoralis and Enterobius 
vermicularis in humans, respectively [19, 20]. In addition, a recent study observed that 
FLOTAC was less sensitive for diagnosing hookworm infections than the Kato-Katz 
method [21], which is contradictory to observations from three other studies [15, 16, 
19]. A further controversial point is that many studies, my own included, detected lower 
mean FEC for FLOTAC in parallel to a higher sensitivity than the comparative method 
[15, 16, 19].  
Chapter 8 - General Discussion and Conclusion 
   
 
-98- 
One explanation for this finding is that the FEC might be overestimated in the case of the 
applied sedimentation technique or Kato-Katz, where the analytical sensitivity is high 
and a large multiplication factor is used for estimating FECs [22, 23][personal 
communication Prof G. Cringoli]. For example, while the FLOTAC technique allow for 
analysing of up to 1 gram of faeces due to its amazing ability to separate faecal debris 
and parasitic eggs, in a single Kato-Katz analysis only 41.7 mg of faeces are used [15, 24]. 
However, another explanation might be that the observed differences in FEC arises, 
because not all the eggs float to the upper layer or additionally they might be cleared by 
preservatives (formaldehyde), ether or the flotation solution itself [21, 25]. Hence, it 
would be interesting to count the eggs in the flotation chamber after translating the 
reading disk in order to estimate the percentage of eggs which did not float or were not 
extracted by translation. Stool samples of experimentally infected laboratory animals 
are, in particular, suitable for these experiments, since these samples are characterised 
by especially high FECs. This experiment is not that easy to perform, because the 
FLOTAC apparatus has to be destroyed in a way, without loosing the faecal sample or re-
combining the translated egg layer with the flotation chamber compartment. To avoid 
this problem, the centrifugal flotation of the eggs could be carried out in a conic tube 
instead of the FLOTAC apparatus and the sediment analysed for remaining eggs.  
To sum up, the egg recovery of FLOTAC might not be as good as that of other 
copromicroscopic techniques resulting in lower FECs, but its ability to analyse a large 
amount of faeces makes it frequently more sensitive than the other techniques.  
 
After analysing more than 500 hundred faecal samples using FLOTAC in my thesis, I 
noticed one important shortcoming, which will be emphasized here. Sometimes 
(interestingly, predominantly observed in rats, which had undergone treatment) the 
reading grid was overfilled with faecal debris, which complicated an accurate counting 
of F. hepatica eggs. Importantly, this phenomenon was never observed with the 
sedimentation techniques. Similar findings have been described for human faecal 
samples [21]. It is not a severe drawback for the detection of F. hepatica eggs, since these 
eggs are large and yellow in colour, but the detection sensitivity of the smaller and 
transparent hookworm eggs and the small-sized intestinal protozoa might be negatively 
impacted. It has been suggested that more organic debris floats and hence worsens the 
microscopic picture, if the lipid content of faecal samples is increased [25]. One might 
speculate that chemotherapy applied to rats might have influenced the faecal 
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composition, possibly triggered by adverse drug reactions or healing process, which 
would explain that contaminated reading slides were mainly observed in treated rats. 
The suggested theory could be verified by analysing faecal samples of people who are 
medicated with orlistat (Xenical®), a lipase inhibitor, and therefore have a higher fat 
level in faeces. The use of an ether or ethyl acetate cleaning step has been proposed to 
overcome this problem [25]. However, it has been shown that ether might negatively 
impact the diagnosis of Ascaris lumbricoides and hookworms [25]. Therefore further 
investigations regarding an improvement of flotation solutions or the use of surface-
active agents (tensides) are needed so that an accurate and robust application is 
possible with the FLOTAC techniques for all the diverse parasites and faecal samples.  
 
Furthermore, it is worthwhile mentioning that FLOTAC is applicable in field conditions 
in developing countries, where poly-parasitism is a norm [26]. Recently, it has been 
shown in several studies, that the FLOTAC techniques can be executed also in rural field 
conditions [16, 20, 27]. This is not that obvious as for example centrifugation is essential 
for faecal sample preparation. Therefore, a special adaptor was produced to connect the 
FLOTAC apparatus with hand centrifuges, which enabled the use of FLOTAC also 
without electricity [20]. FLOTAC holds promise to detect simultaneously the three 
common soil-transmitted helminths (A. lumbricoides, T. trichiura, and hookworms), 
Schistosoma mansoni, and intestinal protozoa infections using only two flotation 
solutions (FS 4 and 7) and might therefore compete with the Kato-Katz method for the 
detection of poly-parasitism [21]. Of note, two different faecal samples can be examined 
simultaneously using a single FLOTAC apparatus. It should be highlighted however, that 
some flotation solutions contain hazardous components such as zinc sulphate, which is 
toxic to water organisms and harmful to users, or mercury iodide, which is additionally 
very poisonous [28]. A proper disposal of the flotation solutions must thus be ensured, 
which is not an issue under laboratory conditions, but might be a limitation of FLOTAC 
under field conditions. Furthermore, it has recently been demonstrated that FLOTAC is 
more expensive than the Kato-Katz method, where the estimated costs to perform a 
duplicate Kato-Katz thick smear and a FLOTAC dual technique were US$ 2.06 and US$ 
2.83, respectively [29]. All these results should be taken into account before deciding 
whether FLOTAC is an applicable diagnostic tool for developing countries.  
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My opinion is that FLOTAC is an excellent invention, which has been shown to be more 
sensitive than comparable copromicroscopic methods. However, its performance is 
difficult, because multiple operation steps including centrifugation, FLOTAC assembly, 
choice of the right flotation solution, and possible additional sample cleaning steps are 
needed to ensure an accurate measurement. Therefore, further investigations are 
needed to improve the robustness of FLOTAC and hence make it simple to perform 
under various conditions. 
 
 
2 Evaluating Drug Activity against F. hepatica 
 
The in vivo and in vitro drug activity of single and combination chemotherapy against  
F. hepatica have been presented in chapter 3 and 4 of the thesis. In brief, intramuscular 
applied artesunate and artemether showed good effects against F. hepatica in naturally 
infected sheep, whereas artesunate was more potent than artemether. This observation 
was different from the one in the rat model, where artemether showed a higher activity. 
Specifically, 50% effective dosages (ED50) of 113, 78, 23, and 2.7 mg/kg were estimated 
for artesunate, artemether, OZ78, and triclabendazole, respectively against adult  
F. hepatica in experimentally infected rats. The juvenile F. hepatica appeared to be less 
susceptible to treatment than adult flukes (for example 5 mg/kg triclabendazole showed 
only marginal effects against juvenile worms, whereas 2.7 mg/kg triclabendazole killed 
approximately 50% of adult F. hepatica in vivo). The sensitivity of adult and juvenile  
F. hepatica to combinations of triclabendazole plus one of the peroxidic drugs, 
artesunate, artemether, and OZ78 was evaluated. The observed drug-drug interactions 
are difficult to interpret and it is therefore not easy to decide how to continue with the 
investigated drug combinations. For example, we observed great variations in 
combinations of artesunate or artemether plus triclabendazole in the dose response 
following slight titrations in the triclabendazole doses. I would therefore like to discuss 
here, how to continue to evaluate drug activity and combination effects against  
F. hepatica, including ethical and methodological considerations. Alternative approaches 
will be suggested here, which might help to improve drug screening and to find effective 
drug combinations.  
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To date, it is not possible to cultivate F. hepatica in vitro throughout the entire life cycle 
[3, 30], and consequently laboratory animals are indispensable for drug screening 
against fascioliasis. However, ethical considerations for how to reduce, refine, and 
replace live animals (3Rs) have to be implemented in the laboratory work [31]. 
Wherever applicable, drug candidates should be screened first in vitro and the most 
promising ones should be selected for in vivo models. Therefore reproducible, accurate, 
and rapid performing in vitro assays are needed. In the case of F. hepatica, drugs can be 
screened in vitro against newly excysted metacercariae/flukes or ex vivo against juvenile 
and adult F. hepatica worms isolated from infected animals [3]. 
 
First, to screen drugs against newly excysted flukes might be the most ethical approach 
because only a few animals are needed to maintain the life-cycle. A further advantage 
might be that drugs can be screened in a medium throughput manner, since numerous 
metacercariae can be harvested from snails, and thus parasite material is not a limiting 
factor [32]. However, metacercariae are expensive to buy particularly due to shipment 
and customs charges. In addition, the entire life cycle would be necessary to generate 
metacercariae in the laboratory, which is difficult because the maintenance of the snails 
is very sensitive. So far we were not successful in maintaining uninfected snails longer 
than a month in our laboratories.  
One could speculate that colorimetric in vitro assays such as Alamar blue or MTT 
formazan could be established for medium throughput screening to assess drug effects 
on newly excysted flukes and replace the so far applied work-intensive phenotype-based 
drug assay [33, 34]. This approach allows the estimation of 50% and 90% effective 
concentrations (EC50/90), and hence enables the comparison of drug candidates and the 
selecting of the most promising candidates for in vivo investigations. Furthermore, if 
drug combinations are evaluated, the precise determination of EC50/90 allows for 
calculating the combination index or the construction of isobolograms, which is required 
to estimate synergism or antagonism between two drugs [35, 36]. One could 
hypothesise, that with such a method it would have been possible to evaluate the 
activity of artesunate, artemether, OZ78, and triclabendazole combinations at several 
concentrations and not only at one fixed concentration as applied in our combination 
chemotherapy study (chapter 3). This may have allowed for a better understanding of 
the interaction between triclabendazole and peroxidic drugs. Nevertheless a 
disadvantage of this screening method might be that novel drug candidates or 
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synergistic drug combinations are missed, since newly excysted flukes were not always 
affected by known fasciocidal drugs [3, 37]. 
Secondly, drugs can be screened ex vivo against juvenile and adult flukes isolated from 
laboratory animals. Of note, in our combination chemotherapy study, juvenile and adult 
F. hepatica worms were used, which were recovered from rats after ineffective 
treatments, and hence our experimental design was limited (a median of 6 to 7  
F. hepatica flukes were recovered from untreated control rats). More ethically, as now 
also done in our laboratories, adult worms can be obtained from naturally infected 
animals, mainly sheep and cattle, from the local slaughterhouse. However, it is difficult 
to plan such experiments, because it is not known when a F. hepatica infected liver can 
be obtained from the slaughterhouse and how many worms can be isolated from it. 
Furthermore, to my knowledge, only phenotype-based assays are currently used for 
drug screening against adult F. hepatica, which are time and work intensive and 
consequently only a few compounds can be tested in a short period. It was not possible 
so far to evaluate drug effect on adults colorimetrically [unpublished observation], 
though microcalorimetry might play a role [38]. 
Another possibility for an F. hepatica assay is to infect rats with approximately 80 
metacercariae and euthanize the rats within 4 weeks post-infection. Hence, the number 
of juvenile flukes recovered from rat livers might be significantly increased. This 
approach allows for a low-medium throughput screening of drugs. In my opinion, it 
would be particularly interesting to evaluate drug activity in a first run against juvenile 
flukes, since many commercially available fasciocidals lack activity against immature 
worms and furthermore a potential drug candidate should be effective against all 
parasite stages (Introduction, Section 7.1). In addition, similarly to in vitro assays of 
newly excysted flukes, the determination of EC50/90 and combination indices would be 
absolutely feasible, since the assays might be performed in 96-well plates using better 
performing screening methods than phenotype-based assays. For example, promising 
results were achieved in our laboratory using a microcalorimetric viability assay to 
evaluate drug efficacy against juvenile F. hepatica [unpublished observation]. However, 
this approach would only be proposed if it can be demonstrated that the ex vivo assay 
against juvenile flukes models the in vivo effect of drugs better than the in vitro assay of 
newly excysted flukes. Moreover, it should be deliberated from an ethical point of view, 
Chapter 8 - General Discussion and Conclusion 
   
 
-103- 
whether rats suffer pain at these high infection intensities, for the larger amount of 
worms recovered.  
 
Promising in vitro or ex vivo activities of lead compounds frequently can not be 
translated to an in vivo efficacy, because biopharmaceutical properties such as low drug 
solubility, poor bioavailability, extensive metabolism, and fast drug elimination might 
negate a potential drug effect [37, 39]. Moreover, with regard to F. hepatica infections, it 
has been shown that the pharmacokinetics of drugs including the artemisinins can be 
altered due to liver damage [40, 41]. In addition, adult flukes lodge in the bile, whereas 
juvenile flukes migrate through the liver and therefore a biphasic activity might only be 
achieved if compounds reach both host organs. It is tempting to speculate that this is a 
reason for many fasciocidals lacking activity against one of the infection stages. 
Additionally, this might be a reason for why the drug combinations showed a lower 
activity against juvenile than against adult worms (chapter 3).  
Given that novel fasciocidal drugs should be active against both stages, in my opinion, in 
vivo drug activity should be assessed first against juvenile and not adult worms, because 
of the following reasons. First, a juvenile infection takes only about 3-4 weeks and is 
therefore less expensive. In addition, rats suffer for a shorter time from the F. hepatica 
infection. Second, one can speculate that more drug candidates fail to be active against 
juvenile worms as opposed to against adult worms and thus fewer animals are used. 
And third, higher infection intensities can be generated in juvenile infections, which 
might improve the interpretation of treatment outcomes. For example, high infection 
intensities of ~200 F. hepatica flukes were observed in experimentally infected sheep 
[42], and hence one could speculate that results obtained in rats with higher infection 
intensities are more representative for the situation in the natural end host sheep.  
 
Our combination chemotherapy study highlighted a substantial loss of precision if egg 
instead of worm counts were used to estimate dose-response relationships (chapter 3). 
Hence, I would suggest using egg analysis only for infection control and for allocating 
rats in treatment groups according to their F. hepatica egg count to equally balance the 
groups. Nevertheless, the faecal egg count reduction test (FECRT) is an important tool to 
evaluate treatment outcome in humans or after drenching farm animals, and is widely 
used in preclinical and clinical studies [43, 44].  
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In conclusion, in a next combination chemotherapy study, it would be advisable to 
incorporate the afore-mentioned approaches and start with evaluating the ex vivo or in 
vitro drug-drug interactions and if promising results arise, in vivo studies in rats can be 
added. In addition, in upcoming studies, it would be wise to focus on a single drug 
combination and only on a single metabolite, which would simplify the whole study 
design and potentially result in a more conclusive outcome. 
 
 
3 Improvement of the LC-MS/MS Method  
 
We developed and validated a LC-MS/MS method for the simultaneous determination of 
artesunate and artemether and their metabolites DHA and DHA-glucuronide in sheep 
plasma. The validation results demonstrated that the LC-MS/MS method is precise, 
accurate, sensitive, and selective and can be applied for the quantification of the 
artemisinins in sheep plasma in pharmacokinetic studies. However, the method has its 
limitations, and therefore feasible improvements of the method should be discussed 
here.    
 
The developed LC-MS/MS method achieved a lower limit of quantification (LLOQ) 
between 10-100 ng/ml depending on the investigated analyte, which is relatively high 
compared to other published methods where LLOQs of about 1 ng/ml were 
demonstrated for this compound class [41, 45-47]. In addition, the performance of the 
method is somewhat outdated; this means long run times of 23 minutes and laborious 
sample work-up. Hence, these variables might be improvable, which would be especially 
important if a high throughput of many samples is needed.  
The method sensitivity may depend amongst others, on the used instrumentation, the 
molecular structure of the analytes, the sample work-up, the mode of analyte detection, 
the selected fragmentation, and the used chromatographic elution. The instrumentation 
and the molecules are more or less fixed parameters, whereas particularly the sample 
work-up, the mode of detection, and the chromatographic settings could be improved.  
In the framework of the method development, the sensitivity and selectivity of the 
method had been rigorously increased by replacing the mode of artemisinins detection 
using selected reaction monitoring (SRM: m/z 267.4→163.0) instead of detecting 
protonated fragments in single MS mode (m/z 221.5, 267.4, and 284.4). This change in 
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detection increased the sensitivity of the artemisinins of about 10-100 times. However, 
at this point of method development we were not able to further enhance the sensitivity 
notably with only small adaptations. The following suggestions might improve the 
method sensitivity and performance significantly.  
An advanced analyte recovery and the reduction of the matrix effect might boost 
sensitivity. It is attractive to speculate, that for instance, the sensitivity of artemether 
could be increased about 3-4 times, in the case suppressing matrix effects could be 
eliminated and a complete recovery could be realized. In retrospect, increased method 
sensitivity would have been valuable, since in our artemether PK study, the 
concentrations of artemether and DHA were low and not quantifiable for some animal at 
each time point (chapter 6). Different operational strategies have been suggested such as 
laborious cleanup procedures, including solid phase or liquid-liquid extraction to 
minimize the interferences of coeluting matrix compounds and consequently to 
eliminate matrix effects [48]. The use of an online solid-phase extraction method using 
column switching systems might be the most promising possibility to minimize matrix 
effects, increase sensitivity, improve analytical separation, and concurrently simplify 
sample work-up [49]. In brief, plasma samples are precipitated and the supernatants are 
injected in the LC-MS/MS system. The analytes are concentrated and cleaned with a 
trapping column and subsequently separated using an analytical column. This technique 
might be less laborious and allow for a much larger sample throughput compared to the 
method we used, since all steps can be accomplished in 96-well plates and there is no 
need for time consuming evaporation of the organic phase [personal communication M. 
Donzelli]. Establishment of an online column switch technique might be of particular 
interest, if the method has to be adapted to analyse bile fluid, since biliary matrix 
components (e.g. biliary salts, biliary acid) might interfere strongly with the analytics 
[50][personal observation]. In addition, this technique would also be useful and 
transferable to the development of analytical methods of upcoming experimental 
fasciocidal analytes.  
A further benefit regarding sample turnover would be to shorten the chromatographic 
elution program of the method. All analytes had to be baseline separated, since they 
were all detected by selected reaction monitoring (SRM) with a similar transition of m/z 
267.4→163.0. The used run time was long, primarily because a slow mobile phase 
gradient had to be applied to separate β-DHA from artesunate. In addition the column 
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had to be washed for several minutes to avoid carry-over effects. However, it might be 
possible to shorten the 23-minute run time using chromatographic columns with 
smaller particles such as pellicular silica columns (Phenomenex Kinetex), as it was 
proposed by one reviewer. Afore-mentioned column-switching techniques might 
additionally assist in shortening the analytical run time. A major upgrade of the method 
would be to detect the artemisinins by multiple reaction monitoring (MRM), given that 
the artemisinins must not be baseline separated and thus the run times can be 
shortened [51][personal communication M. Donzelli]. However, this implies that a 
specific reaction of the parent mass of each artemisinin is monitored and not of an 
identical fragment of the parent mass. Therefore, the parent mass must be ionised in the 
interface of the mass spectrometer but without fragmenting it extensively. The use of 
fragmentation the ammonium ion adducts from the parent mass has been demonstrated 
in other studies, but we were so far not successful with our instrumentation [52, 53]. It 
is tempting to speculate that higher ammonium concentrations added to mobile phase A, 
the use of another interface, or different MS settings might lead to better results. Finally, 
MRM of the parent masses would allow for the usage of isotope-labelled internal 
standards such as artesunate-D4 or artemether-C13-D3, which might positively 
influence the accuracy, since suppressing or enhancing matrix effects can be better 
adjusted [48].   
 
In conclusion, our developed method might be improvable in regard to method 
sensitivity, accuracy, sample throughput, and practicality with moderate adaptations 
without exchanging the whole instrumentation.  
 
 
4 Potential of the Artemisinins for the Treatment of Fascioliasis 
 
Label extension of marketed drugs is one key strategy for drug discovery for tropical 
diseases, because market launch can be achieved with relative speed and limited 
economic cost [54]. The artemisinins may exhibit promise for label extension, since they 
are currently registered for treatment of malaria and promising trematocidal properties 
including Fasciola spp. have been demonstrated [55, 56]. For this reason, it was certainly 
important to investigate the fasciocidal characteristics of the artemisinins, artesunate 
and artemether, during the last years in more detail. Nonetheless, after having taken my 
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personal observations and data from different publications into account, I feel that the 
artemisinins are rather promising lead structures for the development of more active 
next generation analogues than a true alternative to triclabendazole in treatment of 
human and veterinary fascioliasis.  
 
To begin with, reasons are summarized why the sesquiterpene lactone scaffold of the 
artemisinins holds promise to be a lead structure for the development of novel 
fasciocidal drugs. First, artesunate and artemether showed fasciocidal activity in vitro 
and in vivo in the rat and the sheep model [9, 12]. Second, molecules derived from the 
artemisinin core such as the 1,2,4-trioxolanes OZ78 or 1,2,4,5-tetraoxane MT04 showed 
higher activity than the artemisinins itself [10, 38]. Third, the observed activity was not 
stage specific, with both juvenile and adult worms being affected [9, 10, 38]. Fourth, 
artemether and OZ78 were active against a triclabendazole resistant F. hepatica strain, 
and thus it might be speculated that these peroxidic compounds exhibit a different mode 
of action than triclabendazole [11]. In addition, this might be important for the 
development of effective combination treatments. Fifth, to my knowledge neither the 
semisynthetic nor the synthetic artemisinins molecular structures are related to any 
marketed fasciocidals, which underlines the originality of this compound class. Finally, 
the artemisinins showed additional activity against other trematodes including 
Schistosoma, Clonorchis, and Opisthorchis spp., and artemisinin-like structures may 
therefore hold the promise to become a broad spectrum trematocidal drug [56].  
 
Nevertheless, in my opinion the semisynthetic artemisinins might not be an alternative 
to triclabendazole while the synthetic artemisinins, such as OZ78 and MT04, might be 
more promising, based on the following reasons.  
First, triclabendazole exhibit a higher potency than the artemisinins, since we estimated 
an ED50 of 2.7 mg/kg for triclabendazole, which is approximately 30-40 times lower than 
the estimated ED50s of artemether (78 mg/kg) and artesunate (113 mg/kg) following a 
single oral dose in rats. In addition, we could show that OZ78 achieved an improved 
estimated ED50 of 23 mg/kg than the artemisinins. Contradictory results were achieved 
in sheep. While OZ78 failed to cure sheep experimentally infected with F. hepatica, the 
artemisinins were active against F. hepatica in naturally infected sheep [12, 42] (chapter 
4). However, this comparison is incomplete, since the activity of the artemisinins was 
evaluated in sheep with lower infection intensities (natural infections) compared to the 
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study with OZ78. For this reason, I am not so convinced that artemether or artesunate 
could cure high infection intensities in a single dose regimen. Further investigations 
including metabolic, bile and urine excretion studies of OZ78 in sheep and rat are 
needed to understand the discrepancy in activity between the two hosts better (A 
further issue where the column switching technique might become necessary). 
Moreover, two independent clinical studies revealed that artemether lacks activity for 
treatment of chronic human fascioliasis and the response rate in patients treated with 
artesunate was lower than for triclabendazole for the treatment of acute human 
fascioliasis [44, 57]. Still, artesunate may play a role in treatment of acute fascioliasis, as 
patients treated with artesunate were significantly more likely to be free of abdominal 
pain at hospital discharge when compared to triclabendazole-treated patients. Of note, 4 
mg/kg artesunate was applied once daily for 10 days, whereas only two doses of 10 
mg/kg triclabendazole were administered [57].  
A second aspect concerns the safety of the artemisinins treatments. Artesunate and 
artemether exhibit a good safety profile and are well tolerated with only minor adverse 
drug events observable, if applied on a malaria treatment schedule [55]. However, a 
large single oral dose is needed to achieve a high activity against F. hepatica in rats and 
sheep and hence treatment safety was not guaranteed particularly in the case of 
artesunate. For instance, the ED90 of single oral artesunate in rats was calculated at 489 
mg/kg, whereas the 50% lethal dose in healthy rats (LD50) was estimated to be 351 
mg/kg [58]. For comparison, the safety profile of triclabendazole is exceptionally good, 
since we estimated an ED90 of 11.7 mg/kg following a single oral dose in the F. hepatica 
rat model and the LD50 in rats was described to be >8000 mg/kg [4]. In sheep, single 
intramuscular doses of artesunate (<60 mg/kg) were well tolerated and no physical 
clinical sign of toxicity were observed, while double doses of artesunate (40 mg/kg) 
caused death to three of six sheep (chapter 3). Artemether treatment regimens for 
fascioliasis were in general safe; however embryotoxicity in sheep is of concern [12]. 
Importantly, only minor adverse drug events and no severe toxicity was observed in 
OZ78 activity studies in sheep and rats [10, 42].  
A third issue is that artemisinin is required as a precursor molecule for the synthesis of 
artesunate and artemether, which has to be extracted from the leaves of Artemisia 
annua [55]. The herb has to be planted each year and the artemisinin extraction yield 
depends considerably on temperature, humidity, and soil type [55]. For this reason, the 
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chemical purity is of issue as well as the high and volatile artemisinin prices, which is 
controlled by the extraction yields and number of companies extracting artemisinin 
($350-$1700 per kg) [55, 59, 60]. On the other hand, these factors are not present for 
totally synthetic artemisinins such as OZ78, because they exhibit structural simplicity 
and an economically feasible and scalable synthesis [60].  
Finally, the artemisinins are characterised by limiting pharmacokinetics such as poor 
bioavailability and fast elimination [56, 60]. Progress has been made by semisynthetic 
derivatization of the artemisinins, which improved the oral bioavailability and in 
addition enabled the use of different routes of drug administration such as intravenous 
and intramuscular applications [55]. However, the artemisinins were principally 
modified only at one position of the sesquiterpene lactone scaffold, and hence the 
possibility to improve the pharmacokinetic properties is limited. This is in line with the 
experiences we had in the PK study of artemether and artesunate in sheep, where for 
instance, artemether was poorly liberated out of the oil-based intramuscular drug 
formulation with consequently low maximal plasma concentrations. And furthermore, 
both artemisinins were extensively transformed to their glucuronide-metabolite, which 
showed no activity in vitro. Therefore, it is attractive to speculate that other artemisinin 
derivatives than artemether or artesunate, with higher metabolic stability or better 
physicochemical properties, might exhibit better fasciocidal activity. Totally synthetic 
drugs have the great advantage that physicochemical properties as well as structure 
activity relationships can be assessed in the development process of the lead structures, 
whereas these possibilities might be more limited for semi-synthetic drugs [61]. Hence, 
several synthetic artemisinins (such as OZ78) possess an enhanced oral bioavailability 
due to an appropriate balance between lipophilicity and aqueous solubility and 
additionally a longer elimination half-life, and therefore a superior in vivo drug 
disposition over the artemisinins [56, 60].  
 
Taking all points into consideration, it might be reasonable to conclude that the 
artemisinins are promising lead structures for the development of novel fasciocidal 
entities and not yet an alternative to marketed drugs.  
 
 
 
 
Chapter 8 - General Discussion and Conclusion 
   
 
-110- 
Conclusion 
2 
 
In conclusion, in the framework of my PhD thesis, I have worked on different aspects of 
the drug development process ranging from diagnostics, analytics, and 
pharmacokinetics to activity studies in vitro, in rodents and in ruminants (Figure 1).   
The FLOTAC techniques demonstrated a high efficiency and sensitivity for detecting  
F. hepatica eggs in faecal rat samples and have the potential to become a valuable tool 
for experimental work in the F. hepatica rat model. In addition, the FLOTAC techniques 
might be a useful diagnostic tool for other helminth models (e.g. hookworms and 
schistosomes) in our laboratories. Nonetheless, further work is required to achieve a 
better analytical robustness and ease of performance before the FLOTAC techniques can 
compete with established copromicroscopic methods such as the sedimentation 
techniques.  
Artesunate and artemether exhibit interesting fasciocidal activity in vitro and in  
F. hepatica infected rats and sheep. The developed LC-MS/MS method was capable to 
determine PK parameters of the artemisinins and their major metabolites in sheep 
plasma. The main disposition parameters suitably reflected the observed activities of 
artesunate and artemether following different routes of administration against  
F. hepatica in naturally infected sheep. This LC-MS/MS method might be of value to 
determine the artemisinins in other biological fluids including bile and rumen fluid of 
sheep, which might provides further details why oral treatments lacked activity in 
sheep. Combinations with triclabendazole improved the efficacy of the peroxide 
treatments, but in the case of the artemisinins, the observed treatment effect dependent 
on the applied triclabendazole dose. Therefore, further experiments including studies 
using triclabendazole-resistant F. hepatica strains, pharmacokinetic studies and 
combination trials in ruminants, are necessary to thoroughly evaluate the potential of 
triclabendazole-peroxide drug combinations.  
Overall, the novelty of the peroxidic core, the broad spectrum of activity against juvenile 
and adult flukes and the observed activity against a triclabendazole resistant F. hepatica 
strain classify the artemisinins as a lead structure for the development of novel 
peroxidic fasciocidal drugs. 
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